Early and Long-Term Outcomes of Decompensated Heart Failure Patients in a Tertiary-Care Centre in India
Key result
Beta blockers linked to ~43% lower long-term mortality in decompensated HF.
- HR 0.57
- 95% CI 0.49-0.66
- P<0.0001
- n=1,502
Why the study?
Long-term outcome data of acute decompensated HF are scarce from India.
Population
1502 patients admitted with a first episode of decompensated HF in South India
Design
Single-centre registry cohort study
Follow-up
5 and 10year
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change beta-blocker use in decompensated HF; extends observational data to South Indian cohorts but leaves open need for RCTs.
Study Design
Type
Cohort (n=1,502)
Multicenter
No
Structured PICO
P
Population
1,502 consecutive patients admitted with a first episode of decompensated heart failure at a tertiary-care center in India, followed for a median of 3.7 years.
O
Outcome
Early (in-hospital) and late (5 and 10 year) mortalityhard clinical
Main Result
Hazard Ratio: 0.57 (95% CI 0.49–0.66)
p-value: p=<0.0001
In a South Indian cohort of patients with first-episode decompensated heart failure, long-term mortality was high, and guideline-directed medical therapy was associated with improved survival in both HFrEF and HFmrEF.
Cite This Study
Ganapathi et al. (2020) conducted a cohort in Decompensated heart failure (n=1,502). Beta blockers vs. No beta blockers was evaluated on Mortality (HR 0.57, 95% CI 0.49-0.66, p=<0.0001). In patients with decompensated heart failure, the use of beta blockers was associated with a significant reduction in long-term mortality (HR 0.57; 95% CI 0.49-0.66; P<0.0001).